Seasoned Danish stock picker pays researcher to help with corona trial: "We all need a few rays of comfort in this challenging period"

Portfolio manager Michael Voss has given a large sum to Dr. Stig Ekkert, so that he can concentrate exclusively on completing a trial at a danish hospital testing malaria medicine as a treatment for coronavirus.

Photo: Sofia Busk/Jyllands-Posten/Ritzau Scanpix

Michael Voss, who is CEO of Fundamental Fondsmæglerskab, has given Hvidovre hospital a helping hand in the form of economic assistance.

The money will be spent on wages for one of the two researchers at the hospital who have just started a trial to test the effects of malaria medicine klorokin as a preventative and curative treatment for coronavirus.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Nasdaq reports record year in Europe

In 2021, the number of new equity listings on the Nasdaq exchange in Copenhagen broke the old record set in 2007, and in Stockholm, the exchange recorded its highest-ever number of new listings. Nasdaq also had increasing trading volumes last year.

Further reading

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch